ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Drugmaker Takeda to introduce value-based pricing in Europe

Japanese company to refund Crohn's disease patients with no improvements

Biologics, which require complex manufacturing processes, carry hefty price tags.

TOKYO -- Takeda Pharmaceutical will adopt value-based pricing for expensive biopharmaceuticals starting in Europe, becoming the first Japanese drugmaker to test a method that charges only patients whose conditions have improved and possibly igniting a debate for introduction here. 

Takeda is looking to adopt the pricing mechanism for a stem cell therapy called Alofisel for a complication of Crohn's disease. Because of the complex production method that involves cell cultivation, the drug is expected to carry a price tag of an estimated 60,000 euros ($67,000).

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more